Literature DB >> 33364969

CD73: A Promising Biomarker in Cancer Patients.

Roberta Turiello1, Aldo Pinto1, Silvana Morello1.   

Abstract

Entities:  

Keywords:  CD73; adenosine; biomarker; cancer; immunotherapy

Year:  2020        PMID： 33364969      PMCID： PMC7751688          DOI： 10.3389/fphar.2020.609931

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN： 1663-9812            Impact factor:   5.810


× No keyword cloud information.
  51 in total

1.  Serum enzymes in head and neck cancer. IV: 5-nucleotidase.

Authors:  H Lal; L Kumar; G S Kohli; A Sharma; H Goel
Journal:  J Laryngol Otol       Date:  1989-02       Impact factor: 1.469

2.  Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.

Authors:  Aled Clayton; Saly Al-Taei; Jason Webber; Malcolm D Mason; Zsuzsanna Tabi
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

3.  Isolation of biologically-active exosomes from human plasma.

Authors:  Laurent Muller; Chang-Sook Hong; Donna B Stolz; Simon C Watkins; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2014-06-18       Impact factor: 2.303

4.  CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.

Authors:  Shi Yong Neo; Ying Yang; Julien Record; Ran Ma; Xinsong Chen; Ziqing Chen; Nicholas P Tobin; Emily Blake; Christina Seitz; Ron Thomas; Arnika Kathleen Wagner; John Andersson; Jana de Boniface; Jonas Bergh; Shannon Murray; Evren Alici; Richard Childs; Martin Johansson; Lisa S Westerberg; Felix Haglund; Johan Hartman; Andreas Lundqvist
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

5.  CD73 expression in lymph node metastases in patients with head and neck cancer.

Authors:  Magis Mandapathil; Mehtap Boduc; Christoph Netzer; Christian Güldner; Marion Roessler; Ute Wallicek-Dworschak; Evelyn Jahns; Boris Stuck
Journal:  Acta Otolaryngol       Date:  2017-09-22       Impact factor: 1.494

6.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors:  Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

Review 7.  Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.

Authors:  Annette Becker; Basant Kumar Thakur; Joshua Mitchell Weiss; Han Sang Kim; Hector Peinado; David Lyden
Journal:  Cancer Cell       Date:  2016-12-12       Impact factor: 31.743

8.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.

Authors:  Jessica L Bowser; Michael R Blackburn; Gregory L Shipley; Jose G Molina; Kenneth Dunner; Russell R Broaddus
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

9.  Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.

Authors:  Xianhuo Wang; Tingting Zhang; Zheng Song; Linyu Li; Xuhan Zhang; Jing Liu; Xianming Liu; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Lixia Feng; Ge Hu; Bin Meng; Qiongli Zhai; Xiubao Ren; Kai Fu; Lanfang Li; Ping Wang; Huilai Zhang
Journal:  Int J Cancer       Date:  2019-02-04       Impact factor: 7.396

10.  Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.

Authors:  Yusuke Inoue; Katsuhiro Yoshimura; Nobuya Kurabe; Tomoaki Kahyo; Akikazu Kawase; Masayuki Tanahashi; Hiroshi Ogawa; Naoki Inui; Kazuhito Funai; Kazuya Shinmura; Hiroshi Niwa; Takafumi Suda; Haruhiko Sugimura
Journal:  Oncotarget       Date:  2017-01-31
View more
  5 in total

1.  Proteomic Analysis Reveals Differential Expression Profiles in Idiopathic Pulmonary Fibrosis Cell Lines.

Authors:  Juan Manuel Velázquez-Enríquez; Alma Aurora Ramírez-Hernández; Luis Manuel Sánchez Navarro; Itayetzi Reyes-Avendaño; Karina González-García; Cristian Jiménez-Martínez; Luis Castro-Sánchez; Xariss Miryam Sánchez-Chino; Verónica Rocío Vásquez-Garzón; Rafael Baltiérrez-Hoyos
Journal:  Int J Mol Sci       Date:  2022-05-01       Impact factor: 6.208

2.  Identification of CD73 as the Antigen of an Antigen-Unknown Monoclonal Antibody Established by Exosome Immunization, and Its Antibody-Drug Conjugate Exerts an Antitumor Effect on Glioblastoma Cell Lines.

Authors:  Takahiro Anzai; Shinji Saijou; Hiroki Takashima; Misato Hara; Shingo Hanaoka; Yasuhiro Matsumura; Masahiro Yasunaga
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-06

3.  Stem Cell Growth and Differentiation in Organ Culture: New Insights for Uterine Fibroid Treatment.

Authors:  Ana Salas; Silvia Beltrán-Flores; Carmen Évora; Ricardo Reyes; Francisco Montes de Oca; Araceli Delgado; Teresa A Almeida
Journal:  Biomedicines       Date:  2022-06-29

4.  Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.

Authors:  Paolo A Ascierto; Silvana Morello; Roberta Turiello; Mariaelena Capone; Elva Morretta; Maria Chiara Monti; Gabriele Madonna; Rosa Azzaro; Pasquale Del Gaudio; Ester Simeone; Antonio Sorrentino
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

Review 5.  Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma.

Authors:  Brecht Decraene; Yihan Yang; Patrizia Agostinis; Steven De Vleeschouwer; Frederik De Smet; Abhishek D Garg
Journal:  Genes Immun       Date:  2022-01-19       Impact factor: 2.676
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.